Free shipping on all orders over $ 500

LY2409881 trihydrochloride

Cat. No. M8961

All AbMole products are for research use only, cannot be used for human consumption.

LY2409881 trihydrochloride Structure
Size Price Availability Quantity
5mg USD 130 In stock
10mg USD 215 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY2409881 trihydrochloride is a potent and selective IKK2 inhibitor with IC50 of 30 nM. LY2409881 trihydrochloride inhibits constitutively activated NF-ƘB, and causes concentration- and time-dependent growth inhibition and apoptosis in diffuse large B-cell lymphoma (DLBCL) cells. In the ovarian cancer cell line SKOV3, LY2409881 demonstrates moderate cytotoxicity. LY2409881 trihydrochloride is synergistic with doxorubicin and cyclophosphamide in SUDHL2 cell in inhibiting the cell growth, but not in LY1 cell.

In vivo, LY2409881 (50, 100, and 200 mg/kg, i.p.) significantly inhibits the tumor growth in SCID-beige xenograft mouse model.

Protocol (for reference only)
Cell Experiment
Cell lines OCI-LY10 cells
Preparation method Cytotoxicity is evaluated using the CellTiter-Glo Reagent according to the manufacturer's manual. Experiments are carried out in 96-well plates, with each treatment in triplicate. Samples are taken at typically 24, 48, and 72 hours after treatment. Cytotoxicity is expressed by the decreasing percentage of live cells in each treatment relative to the untreated control from the same experiment. IC50 for each cell line is calculated using the CalcuSyn Version 2.0 software.
Concentrations 25 μM
Incubation time ~72 h
Animal Experiment
Animal models Five- to 7-week-old SCID beige mice
Formulation 5% dextrose in water
Dosages 50, 100, 200 mg/kg on day 1 and 4 of every week for 4 weeks
Administration administered intraperitoneally
Chemical Information
Molecular Weight 594.43
Formula C24H32Cl4N6OS
CAS Number 946518-60-1
Solubility (25°C) DMSO: ≥ 16 mg/mL warmed
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Deng C, et al. Clin Cancer Res. The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB.

Related IκB/IKK Products
BAY 11-7082

BAY 11-7082 is an inhibitor of cytokine-induced IκB-α phosphorylation (IC50 ~ 10 μM). BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively).

SC-514

SC-514 is a selective and reversible inhibitor of IκB kinase 2 (IKK2) with IC50 of 3-12 μM.

TPCA-1

TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM.

BMS-345541 hydrochloride

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IC50 values of 0.3 μM and 4 μM for IKK-2 and IKK-1 respectively). BMS-345541 binds at an allosteric site of IKK.

Bardoxolone Methyl

Bardoxolone Methyl is an IKK inhibitor with potent pro-apoptotic and anti-inflammatory activities, as well as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway.

  Catalog
Abmole Inhibitor Catalog




Keywords: LY2409881 trihydrochloride supplier, IκB/IKK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.